Skip to main content
GENETIC TECHNOLOGIES LIMITED logo

GENETIC TECHNOLOGIES LIMITED — Investor Relations & Filings

Ticker · GTG ISIN · AU000000GTG7 LEI · 529900YYKY7FRC90M744 ASX Human health and social work activities
Open in API
Filings indexed 1,303 across all filing types
Latest filing 2015-06-14 Board/Management Inform…
Country AU Australia
Listing ASX GTG

About GENETIC TECHNOLOGIES LIMITED

https://gtglabs.com/

Genetic Technologies Limited is a molecular diagnostics company focused on the development and commercialization of predictive genetic risk assessment tools. The company specializes in the geneType platform, which integrates clinical risk factors with polygenic risk scores to provide comprehensive risk assessments for various chronic diseases. Its portfolio includes tests for breast cancer, colorectal cancer, prostate cancer, melanoma, type 2 diabetes, and coronary artery disease. By identifying individuals at high risk of developing these conditions, the company enables healthcare providers to implement personalized screening and preventative health strategies. Genetic Technologies Limited serves clinicians and patients globally, aiming to improve health outcomes through early detection and precision medicine.

Recent filings

Filing Released Lang Actions
Appointment of Chief Financial Officer 1 page 140.0
Board/Management Information Classification · 95% confidence The document is an ASX announcement dated 15 June 2015 regarding the appointment of a new Chief Financial Officer. It contains biographical details about the appointee and company background information. There are no financial statements, earnings data, or detailed financial analysis. The document is a management announcement about a change in senior management. It is not a report, earnings release, or regulatory filing. Therefore, the appropriate classification is Board/Management Information (MANG). The document length is 3606 characters, which is consistent with a typical management announcement rather than a full report.
2015-06-14 English
Change in substantial holding 5 pages 488.6KB
Regulatory Filings
2015-06-11 English
Appointment of Executive Director 4 pages 148.2KB
Board/Management Information Classification · 100% confidence The document is an ASX announcement dated 12 June 2015 regarding the appointment of an Executive Director, Mr. Eutillio Buccilli, to the Board of Genetic Technologies Limited. It includes biographical details, the context of the appointment, and an Appendix 3X Initial Director’s Interest Notice, which is a regulatory form related to director shareholdings and interests. The content focuses on management changes and director interests rather than financial results, audit information, or other report types. The document length is 7,839 characters, which is sufficient for a full announcement but does not contain financial statements or detailed financial analysis. Therefore, the document fits best under the category of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2015-06-11 English
GTG supports research findings 2 pages 140.3KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 29 May 2015 from Genetic Technologies Limited. It discusses the company's support for research findings related to gene-panel sequencing and breast cancer risk, referencing a special report in The New England Journal of Medicine. The content is primarily a commentary on scientific research and the company's product validation, with no financial data, regulatory filings, or report attachments. It does not contain financial statements, management discussion, voting results, or any other formal report content. The document is a public announcement providing information about the company's stance on recent research findings, typical of a general regulatory announcement or company update. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous announcements that do not fit other specific categories.
2015-05-28 English
Nasdaq Deficiencies Update 2 pages 148.0KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 4 May 2015 from Genetic Technologies Limited regarding the remediation of Nasdaq listing deficiencies related to minimum stockholders' equity requirements. It references prior announcements and details various capital raising activities and transactions that have enabled the company to regain compliance with Nasdaq listing rules. The document does not contain financial statements or detailed financial analysis but rather reports on compliance status and capital raising events. It is a regulatory announcement about the company's listing status and capital structure compliance, not a full financial report or earnings release. Therefore, it fits best under Capital/Financing Update (CAP). The document length (6821 characters) supports it being a detailed announcement rather than a brief notice or a full report.
2015-05-03 English
Quarterly Activites Report - 31 March 2015 12 pages 422.6KB
Regulatory Filings
2015-04-26 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.